The seasonal influenza vaccines market in the US, Japan and five major European markets (France, Germany, Italy, Spain and the UK) is expected to continue to expand over the next 10 years, largely due to the ongoing uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Sanofi’s Fluzone High-Dose and CSL Seqirus’s Fluad. Further to this, an aging population in the US, Japan, five major European markets and other developed countries will increase the number of patients in the ≥65 years age group, where coverage rates are higher. Additionally, the COVID-19 pandemic has prompted a surge in demand for influenza vaccines due to heightened public awareness of the threat posed by respiratory viruses to the elderly and those with co-morbidities, as well as the potential burden on healthcare services of coinciding COVID-19 and influenza waves.